New Delhi, March 17 Zydus Lifesciences announced on Tuesday that it has entered into a licensing and supply agreement with Lupin to expand access to the diabetes treatment drug Semaglutide Injection (15 mg/3 ml) with a patient-friendly, reusable pen device in India.
The agreement aims to strengthen patient access to advanced diabetes and weight management therapies.
Under the agreement, Lupin will have semi-exclusive rights to co-market Zydus' innovative Semaglutide Injection in the Indian market under the brand names Semanext and Livarise.
Zydus will market the product under the brand names Semaglyn, Mashema, and Altermet.
Lupin will pay Zydus upfront licensing fees and milestone payments upon achieving pre-defined milestones.
"Our life-changing discoveries are empowering patients to live healthier, more fulfilling lives. With patients' needs and convenience at the core, the innovative pen device we are offering is designed to simplify therapy and improve quality of life," said Zydus Lifesciences MD Sharvil Patel in a statement.
Lupin MD Nilesh Gupta said the partnership with Zydus to market Semaglutide injection in India is a significant step in strengthening the company's commitment to providing advanced treatment options for cardio-metabolic diseases.
"As GLP 1 therapies continue to redefine treatment standards globally, this collaboration enhances our diabetes portfolio and reinforces our focus on addressing unmet patient needs. Together, we aim to expand access to innovative, high-quality treatment options for patients and support healthcare professionals across India," he added.
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
It is also indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults.
